Vishal Sikri, Executive Vice President of Commercial at Myriad Genetics Inc, filed a Form 4 on November 9, 2026, disclosing the grant of a time-based stock option covering 53,236 shares of common stock as a one-time retention award.

Key Highlights

  • Reporting person: Vishal Sikri, EVP, Commercial at Myriad Genetics Inc (NASDAQ:MYGN)
  • Grant date: November 6, 2026, with the transaction code recorded as "A" (acquired)
  • Option size: 53,236 non-qualified stock options granted under the 2026 Employee, Director and Consultant Equity Incentive Plan
  • Exercise price: $5.92 per share, described as equal to the closing price of common stock on the grant date
  • Vesting: The option vests in full on November 6, 2029, subject to continued service through that date
  • Expiration date: November 6, 2036
  • Price paid for the grant: $0

Details of Vishal Sikri's Retention Option Grant at Myriad Genetics

According to the Form 4 filed with the SEC on November 9, 2026, Vishal Sikri, who serves as Executive Vice President of Commercial at Myriad Genetics Inc (NASDAQ:MYGN), received a grant of 53,236 time-based non-qualified stock options on November 6, 2026. The filing identifies the award as "a one-time non-qualified stock option granted as a retention award" under the issuer's 2026 Employee, Director and Consultant Equity Incentive Plan.

The options carry an exercise price of $5.92 per share, which the filing states equals the closing price of the issuer's common stock on November 6, 2026, the grant date. No cash consideration was paid by Sikri for the grant, as the filing records a price of $0 for the derivative security. Following this transaction, Sikri directly holds 53,236 derivative securities beneficially owned.

The filing discloses that the option vests and becomes exercisable in full on November 6, 2029, contingent on Sikri's continued service through that date and compliance with the terms and conditions of the plan and the applicable award agreement. The option expires on November 6, 2036. The Form 4 was signed by Justin Hunter on behalf of Vishal Sikri and filed on November 9, 2026.

What Was Disclosed

Myriad Genetics EVP Vishal Sikri disclosed the receipt of 53,236 non-qualified stock options at an exercise price of $5.92 per share, granted November 6, 2026, as a one-time retention award vesting in full on November 6, 2029, with no cost to the reporting person.